JEA BizDev Consulting, LLC®
Let’s connect
JEA BizDev Consulting, LLC®

Science. Strategy. Partnership.

Reference libraries
My cross-border dealsCross-border deal library
Start a conversation
North America · Europe · Asia

Find your next opportunity.

HomeConnecting science. Creating value.PagesServicesExpertise across the BD value chainPagesAbout JohnExperience behind the partnershipsPagesOur approachFrom strategy to signed agreementPagesOpportunitiesExplore assets for partneringPagesTrack recordPartnerships and downloadable deal summariesPagesStart a conversationDiscuss an opportunity with JohnPagesMy cross-border dealsJEA reference library on Google DriveTransactionsCross-border deal libraryJEA reference library on Google DriveTransactionsDLL3 ADCOncology · IND Filing · DLL3AssetsHER2 Biparatopic ADCOncology · Phase 3 · HER2AssetsFRα Biparatopic ADCOncology · IND Filing · FRαAssetsCYP11B2 InhibitorCardiovascular · IND Filing · CYP11B2AssetsENPP1 InhibitorCardiovascular · IND Approved · ENPP1AssetsB7-H3 ADCOncology · Phase 1 · B7-H3AssetsATM InhibitorOncology · Phase 1 · ATMAssetsKAT6 InhibitorOncology · Phase 1 · KAT6A / KAT6BAssetsEGFR-ADCOncology · Phase 3 · EGFRAssetsNovaRock × Bionyra (2026)Exclusive license agreement for NBL-023, a novel anti–IL-25 monoclonal antibody, granting worldwide rights outside Greater China.TransactionsNovaRock × LigaChemBio (2026)Global out-licensing agreement for an ADC candidate targeting a novel oncology antigen.TransactionsCSPC × Radiance Biopharma (2025)$1,240 million strategic partnership for ROR1-ADC (SYS6005).TransactionsCSPC × Cipla (2025)$1,065 million strategic partnership for an Irinotecan Liposomal Injection product.TransactionsNovaRock × LigaChemBio (2025)Two global out-licensing agreements for novel antibodies.Transactions
↑ ↓ Navigate · Enter Open · Esc Close

AVAILABLE ASSETS

The science of possibility.

Strategic partnering opportunities in oncology and cardiovascular disease. Explore assets by target, modality, and development stage.

9 opportunities · Overview decks available upon request

Oncology

HER2 Biparatopic ADC

Antibody-Drug Conjugate
Target: HER2

Phase 3Explore asset
Oncology

EGFR-ADC

Antibody-Drug Conjugate
Target: EGFR

Phase 3Explore asset
Oncology

B7-H3 ADC

Antibody-Drug Conjugate
Target: B7-H3

Phase 1Explore asset
Oncology

ATM Inhibitor

Small Molecule
Target: ATM

Phase 1Explore asset
Oncology

KAT6 Inhibitor

Small Molecule
Target: KAT6A / KAT6B

Phase 1Explore asset
Cardiovascular

ENPP1 Inhibitor

Small Molecule
Target: ENPP1

IND ApprovedExplore asset
Oncology

DLL3 ADC

Antibody-Drug Conjugate
Target: DLL3

IND FilingExplore asset
Oncology

FRα Biparatopic ADC

Antibody-Drug Conjugate
Target: FRα

IND FilingExplore asset
Cardiovascular

CYP11B2 Inhibitor

Small Molecule
Target: CYP11B2

IND FilingExplore asset

THE NEXT CONVERSATION COULD CHANGE EVERYTHING

Great science deserves
the right partnership.

Let’s talk about where you want to go,
and how we can help you get there.

Start a conversation